Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elobixibat - Albireo Pharma/EA Pharma

Next Previous
Drug Profile

Elobixibat - Albireo Pharma/EA Pharma

Alternative Names: A-3309; AJG-533; Goofice

Latest Information Update: 06 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Albireo Pharma; EA Pharma; Eisai Co Ltd; Mochida Pharmaceutical; Synmosa Biopharma; Yokohama City University
  • Class 2 ring heterocyclic compounds; Amides; Antihyperlipidaemics; Carboxylic acids; Hepatoprotectants; Irritable bowel syndrome therapies; Laxatives; Small molecules; Sulfides; Sulfones; Thiazepines
  • Mechanism of Action Sodium-bile acid cotransporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation
  • Discontinued Dyslipidaemias; Irritable bowel syndrome; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 02 Mar 2023 Albireo Pharma has been acquired by Ipsen
  • 31 Dec 2021 Albireo Pharma has patent protection for elobixibat in USA and Japan
  • 31 Dec 2021 Albireo Pharma has patent protection for methods of use of elobixibat for chronic constipation in USA, Europe and Japan

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top